Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.
AuthorsJanetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A,
JournalCancer Immunol Immunother
PubMed ID19894047
'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause ... More
Impact of culture medium on the expansion of T cells for immunotherapy.
AuthorsSato K, Kondo M, Sakuta K, Hosoi A, Noji S, Sugiura M, Yoshida Y, Kakimi K,
JournalCytotherapy
PubMed ID19903105
'BACKGROUND AIMS: Encouraging evidence of clinical benefits from cancer immunotherapy is beginning to accumulate in several clinical trials. Cancer immunotherapy is based on two main methods, active vaccination and cell-transfer therapy. The ex vivo expansion of T cells is required to monitor vaccine-induced antigen-specific T cells or prepare large numbers ... More
Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement.
AuthorsSmith C, Økern G, Rehan S, Beagley L, Lee SK, Aarvak T, Schjetne KW, Khanna R
Journal
PubMed ID25671129
The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens ... More
Bioengineering and serum free expansion of blood-derived ?d T cells.
AuthorsSutton KS, Dasgupta A, McCarty D, Doering CB, Spencer HT
JournalCytotherapy
PubMed ID27260209
'Cellular immunotherapy relies on several highly variable patient-specific parameters, such as (i) cell number before and after expansion, (ii) targeting of cells to tumors, (iii) cell survival and function after infusion, and (iv) on- and off-target adverse events. Cellular approaches such as the specific expansion of ?d T cells as ... More
A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.
AuthorsLu TL, Pugach O, Somerville R, Rosenberg SA, Kochendefer JN, Better M, Feldman SA
JournalHum Gene Ther Methods
PubMed ID27897048
The treatment of B-cell malignancies by adoptive cell transfer (ACT) of anti-CD19 chimeric antigen receptor T cells (CD19 CAR-T) has proven to be a highly successful therapeutic modality in several clinical trials.(1-6) The anti-CD19 CAR-T cell production method used to support initial trials relied on numerous manual, open process steps, ... More
Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.
AuthorsMorera Y, Sánchez J, Bequet-Romero M, Selman-Housein KH, de la Torre A, Hernández-Bernal F, Martín Y, Garabito A, Piñero J, Bermúdez C, de la Torre J, Ayala M, Gavilondo JV
JournalVaccine
PubMed ID28536029
CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a bacterially-derived adjuvant. The vaccine have demonstrated efficacy in several murine malignancy models. These studies supported the rationale for a phase I clinical trial where safety, ... More
Enhancing adoptive cancer immunotherapy with V?2Vd2 T cells through pulse zoledronate stimulation.
AuthorsNada MH, Wang H, Workalemahu G, Tanaka Y, Morita CT
JournalJ Immunother Cancer
PubMed ID28239463
Human ?d T cells expressing V?2Vd2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with V?2Vd2 T cells has been used to treat cancer patients with partial and complete remissions. Most clinical trials and preclinical studies have ... More